- Rexahn Awarded U.S. Patent for Novel Anti-Cancer Compounds
June 17th, 2013 - Rexahn Pharmaceuticals to Present at the Second Annual Marcum LLP Microcap Conference
May 20th, 2013 - Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013
April 2nd, 2013 - Rexahn Pharmaceuticals Provides Key Goals for 2013
February 19th, 2013 - Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer
January 22nd, 2013 - Rexahn Pharmaceuticals Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds
December 17th, 2012 - Rexahn Pharmaceuticals Closes Public Offering for $6,600,000 in Gross Proceeds
December 4th, 2012 - Rexahn Pharmaceuticals Prices Public Offering of Stock
November 29th, 2012 - Rexahn Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrant
November 28th, 2012 - Teva Pharmaceutical to Increase Ownership in Rexahn
November 28th, 2012
2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003